Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer

39Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: The aim of our study was to evaluate the prognostic role of immunological microenvironnement in stage II-III CRC patients. Methods: We constructed a tissue microarray from 196 consecutive patients with stage II-III CRC and compared CD3, CD4, CD8, CD57, CD68, CXCL9/MIG, CXCL13, and PPARγ immunoreactivity in tumour samples and their matched non-tumour tissue. We assessed their association with relapse-free survival (RFS; primary endpoint) and overall survival (OS) in multivariate Cox models. Results: Low densities of CD57+ and CD68+ tumour-infiltrating cells (TIC) independently predicted worse outcomes. A prognostic score combining CD57 (+, > vs-, ≤2 cells per spot) and CD68 (+, >0 vs-, =0 cells per spot) TIC density discriminated CRC patients at low (CD68+/CD57+), intermediate (CD68+/CD57-), or high (CD68-/CD57-) risk, with hazard ratios for the intermediate-risk and high-risk groups of 2.7 (95% confidence interval (CI): 1.3-5.8) and 9.0 (3.2-25.4) for RFS, and 2.5 (1.2-5.1) and 10.6 (3.8-29.2) for OS, respectively, as compared with the low-risk group. Corresponding 5-year survival rates (95% CI) in the low-, moderate-And high-risk groups were 84% (71-91), 65% (54-74), and 12% (2-47), respectively, for RFS, and 91% (80-96), 76% (66-84), and 25% (7-59), respectively, for OS. Conclusion: Tumour CD57+ and CD68+ TIC density assessment independently predicts survival in patients with stage II-III CRC. If validated, our score based on a quick, inexpensive, and well-established method such as point counting on diagnostic tissue sections could be used routinely as a prognostic tool in CRC patients. © 2013 Cancer Research UK. All rights reserved.

Cite

CITATION STYLE

APA

Chaput, N., Svrcek, M., Aupérin, A., Locher, C., Drusch, F., Malka, D., … Boige, V. (2013). Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer. British Journal of Cancer, 109(4), 1013–1022. https://doi.org/10.1038/bjc.2013.362

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free